These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29709478)

  • 1. Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.
    Yu YL; Diao NN; Li YZ; Meng XH; Jiao WL; Feng JB; Liu ZP; Lu N
    Biochem Biophys Res Commun; 2018 Jun; 501(2):380-386. PubMed ID: 29709478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
    Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
    J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    Xiao X; Yang G; Bai P; Gui S; Nyuyen TM; Mercado-Uribe I; Yang M; Zou J; Li Q; Xiao J; Chang B; Liu G; Wang H; Liu J
    BMC Cancer; 2016 Aug; 16():582. PubMed ID: 27484466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C iota promotes glycolysis via PI3K/AKT/mTOR signalling in high grade serous ovarian cancer.
    Tyagi K; Roy A; Mandal S
    Mol Biol Rep; 2024 Sep; 51(1):983. PubMed ID: 39276277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.
    Karagoz K; Mehta GA; Khella CA; Khanna P; Gatza ML
    EBioMedicine; 2019 Dec; 50():191-202. PubMed ID: 31767542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells.
    Park SH; Song JY; Kim YK; Heo JH; Kang H; Kim G; An HJ; Kim TH
    Int J Oncol; 2014 Mar; 44(3):637-46. PubMed ID: 24378809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner.
    Wang Y; Qiu C; Lu N; Liu Z; Jin C; Sun C; Bu H; Yu H; Dongol S; Kong B
    Int J Oncol; 2018 Jun; 52(6):2130-2142. PubMed ID: 29620165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.
    Hooda J; Novak M; Salomon MP; Matsuba C; Ramos RI; MacDuffie E; Song M; Hirsch MS; Lester J; Parkash V; Karlan BY; Oren M; Hoon DS; Drapkin R
    Cancer Res; 2019 Feb; 79(4):760-772. PubMed ID: 30563893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma.
    Jin Y; Zou Y; Wan L; Lu M; Liu Y; Huang G; Wang J; Xi Q
    Mol Med Rep; 2018 Apr; 17(4):5409-5415. PubMed ID: 29393455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical significance and biological function of lncRNA SOCAR in serous ovarian carcinoma.
    Guo Q; Wang L; Zhu L; Lu X; Song Y; Sun J; Wu Z; Shi J; Wang Z; Zhou X
    Gene; 2019 Sep; 713():143969. PubMed ID: 31299360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma.
    Kurimchak AM; Herrera-Montávez C; Brown J; Johnson KJ; Sodi V; Srivastava N; Kumar V; Deihimi S; O'Brien S; Peri S; Mantia-Smaldone GM; Jain A; Winters RM; Cai KQ; Chernoff J; Connolly DC; Duncan JS
    Sci Signal; 2020 Feb; 13(619):. PubMed ID: 32071169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
    Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
    Cancer Lett; 2021 Mar; 501():224-233. PubMed ID: 33221455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
    BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High expression of ENPP1 in high-grade serous ovarian carcinoma predicts poor prognosis and as a molecular therapy target.
    Wang H; Ye F; Zhou C; Cheng Q; Chen H
    PLoS One; 2021; 16(2):e0245733. PubMed ID: 33635867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA ZFAS1 interacts with miR-150-5p to regulate Sp1 expression and ovarian cancer cell malignancy.
    Xia B; Hou Y; Chen H; Yang S; Liu T; Lin M; Lou G
    Oncotarget; 2017 Mar; 8(12):19534-19546. PubMed ID: 28099946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
    Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
    Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An immunohistochemical comparison of P53 and Bcl-2 as apoptotic and MIB1 as proliferative markers in low-grade and high-grade ovarian serous carcinomas.
    Mishra SK; Crasta JA
    Int J Gynecol Cancer; 2010 May; 20(4):537-41. PubMed ID: 20442586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Increased n-acetylaspartate Levels in Cancer.
    Zand B; Previs RA; Zacharias NM; Rupaimoole R; Mitamura T; Nagaraja AS; Guindani M; Dalton HJ; Yang L; Baddour J; Achreja A; Hu W; Pecot CV; Ivan C; Wu SY; McCullough CR; Gharpure KM; Shoshan E; Pradeep S; Mangala LS; Rodriguez-Aguayo C; Wang Y; Nick AM; Davies MA; Armaiz-Pena G; Liu J; Lutgendorf SK; Baggerly KA; Eli MB; Lopez-Berestein G; Nagrath D; Bhattacharya PK; Sood AK
    J Natl Cancer Inst; 2016 Jan; 108(6):djv426. PubMed ID: 26819345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ELF5 in epithelial ovarian carcinoma tissues and biological behavior in ovarian carcinoma cells.
    Yan H; Qiu L; Xie X; Yang H; Liu Y; Lin X; Huang H
    Oncol Rep; 2017 Mar; 37(3):1412-1418. PubMed ID: 28184931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.